Literature DB >> 21932027

Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Dirk Rades1, Nina D Seibold, Maximilian P Gebhard, Frank Noack, Steven E Schild, Christoph Thorns.   

Abstract

BACKGROUND AND
PURPOSE: The prognosis of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) is generally poor. However, prognostic factors can help optimize the care for the individual patient. This study investigated potential prognostic factors, including HPV status, for locoregional control (LRC), metastases-free survival (MFS), and survival (OS). PATIENTS AND METHODS: Twelve potential prognostic factors were investigated in 170 patients irradiated for stage III or IV SCCHN, including age (≤ 60 vs > 60 years), gender, ECOG performance score (0-1 vs 2), preradiotherapy hemoglobin level (< 12 vs ≥ 12 g/dl), tumor site (oropharynx, oral cavity, hypopharynx, or larynx), histological grade (G1-2 vs G3), T category (T1-T2 vs T3-T4), N category (N0-N1 vs N2-N3), AJCC stage (III vs IV), surgery (no vs yes), and chemotherapy (no vs yes).
RESULTS: On multivariate analysis, positive HPV status (RR 2.34; p = 0.014), ECOG performance score 0-1 (RR 1.94; p = 0.017), preRT hemoglobin ≥ 12 g/dl (RR 1.88; p = 0.018), T category T1-T2 (RR 2.72; p < 0.001), and surgery (RR 2.29; p = 0.007) were significantly associated with improved LRC. PreRT hemoglobin ≥ 12 g/dl (RR 1.98; p = 0.040) and T category T1-T2 (RR 3.33; p < 0.001) were significantly associated with improved MFS. Positive HPV status (RR 2.19; p = 0.019), pre-RT hemoglobin ≥ 12 g/dl (RR 2.15; p = 0.002), T category T1-T2 (RR 2.31; p = 0.002), and AJCC stage III (RR 1.91; p = 0.034) were significantly associated with improved OS.
CONCLUSION: Improved treatment outcomes were significantly associated with positive HPV status, better performance status, lower tumor stage, and pretreatment hemoglobin levels ≥ 12 g/dl. These factors should be considered in future trials.

Entities:  

Mesh:

Year:  2011        PMID: 21932027     DOI: 10.1007/s00066-011-1139-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  29 in total

1.  Investigations on parotid gland recovery after IMRT in head and neck tumor patients.

Authors:  Markus Stock; Wolfgang Dörr; Carmen Stromberger; Ulrike Mock; Susanne Koizar; Richard Pötter; Dietmar Georg
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

2.  High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.

Authors:  Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

3.  Brachial plexopathy after chemoradiotherapy for head and neck squamous cell carcinoma.

Authors:  Nele Platteaux; Piet Dirix; Robert Hermans; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

4.  Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas.

Authors:  A Becker; P Stadler; R S Lavey; G Hänsgen; T Kuhnt; C Lautenschläger; H J Feldmann; M Molls; J Dunst
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

5.  Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6∗I.

Authors:  Ervinna Pang; Naomi C Delic; Angela Hong; Mei Zhang; Barbara R Rose; J Guy Lyons
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-23       Impact factor: 7.038

Review 6.  Unravelling the biology of human papillomavirus (HPV) related tumours to enhance their radiosensitivity.

Authors:  Marie-Catherine Vozenin; Hannah-Kate Lord; Dana Hartl; Eric Deutsch
Journal:  Cancer Treat Rev       Date:  2010-04-22       Impact factor: 12.111

7.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Authors:  Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

8.  The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database.

Authors:  S A Leibel; C B Scott; M Mohiuddin; V A Marcial; L R Coia; L W Davis; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-08       Impact factor: 7.038

9.  Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT.

Authors:  Anjali K Gupta; John H Lee; Werner W Wilke; Harry Quon; Gareth Smith; Amit Maity; John M Buatti; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-01       Impact factor: 7.038

10.  Inter-laboratory validation of PCR-based HPV detection in pathology specimens.

Authors:  Iver Petersen; Christiane Schewe; Karsten Schlüns; Manfred Dietel; Norbert Speich; Christoph Schmitt; Magdolna Bollmann; Karl Sotlar; Burkhard Bültmann; Maria T Dours-Zimmermann; Barbara Padberg; Dieter R Zimmermann
Journal:  Virchows Arch       Date:  2007-07-10       Impact factor: 4.535

View more
  24 in total

1.  Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.

Authors:  J Cvek; J Kubes; E Skacelikova; B Otahal; P Kominek; M Halamka; D Feltl
Journal:  Strahlenther Onkol       Date:  2012-06-01       Impact factor: 3.621

2.  High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer.

Authors:  O P Erpolat; P U Gocun; M Akmansu; E Karakus; G Akyol
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

3.  Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma.

Authors:  A K Due; I R Vogelius; M C Aznar; S M Bentzen; A K Berthelsen; S S Korreman; C A Kristensen; L Specht
Journal:  Strahlenther Onkol       Date:  2012-05-13       Impact factor: 3.621

4.  Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.

Authors:  Nicolas Dornoff; Christian Weiß; Franz Rödel; Jens Wagenblast; Shahram Ghanaati; Nateghian Atefeh; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2015-05-25       Impact factor: 3.621

5.  Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems.

Authors:  Edgar Selzer; Anja Grah; Gregor Heiduschka; Gabriela Kornek; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2015-01-13       Impact factor: 3.621

6.  Modification of staging and treatment of head and neck cancer by FDG-PET/CT prior to radiotherapy.

Authors:  A Abramyuk; S Appold; K Zöphel; M Baumann; N Abolmaali
Journal:  Strahlenther Onkol       Date:  2013-01-19       Impact factor: 3.621

Review 7.  The role of human papillomavirus in oral squamous cell carcinoma: myth and reality.

Authors:  Katinka Kansy; Oliver Thiele; Kolja Freier
Journal:  Oral Maxillofac Surg       Date:  2012-12-16

8.  Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R.

Authors:  N D Seibold; S E Schild; M P Gebhard; F Noack; U Schröder; D Rades
Journal:  Strahlenther Onkol       Date:  2013-05-24       Impact factor: 3.621

9.  Importance of tumor volume in supraglottic and glottic laryngeal carcinoma.

Authors:  L W van Bockel; E M Monninkhof; F A Pameijer; C H J Terhaard
Journal:  Strahlenther Onkol       Date:  2013-11-08       Impact factor: 3.621

10.  Xerostomia after radiotherapy. What matters--mean total dose or dose to each parotid gland?

Authors:  S Tribius; J Sommer; C Prosch; A Bajrovic; A Muenscher; M Blessmann; A Kruell; C Petersen; M Todorovic; P Tennstedt
Journal:  Strahlenther Onkol       Date:  2013-01-27       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.